A New Prostate Cancers Treatment Strategy

A New Prostate Cancers Treatment Strategy.
Conventional perceptiveness has it that steep levels of testosterone help prostate cancers grow. However, a new, small research suggests that a treatment strategy called bipolar androgen therapy - where patients substitute between low and high levels of testosterone - might make prostate tumors more responsive to required hormonal therapy. As the researchers explained, the primary treatment for advanced prostate cancer is hormonal therapy, which lowers levels of testosterone to stave off the tumor from growing look at this. But there's a problem: Prostate cancer cells inevitably whip the therapy by increasing their ability to suck up any unconsumed testosterone in the body.

The new strategy forces the tumor to respond again to higher testosterone levels, help to reverse its resistance to standard therapy, the researchers say click for source. If confirmed in several evolving larger trials, "this could lead to a new treatment approach" for prostate cancers that have grown opposed to hormonal therapy, said lead researcher Dr Michael Schweizer, an deputy professor of oncology at the University of Washington School of Medicine in Seattle.

So "It needs to be stressed that bipolar androgen group therapy is not ready for adoption into routine clinical practice, since these studies have not been completed. The publicize was published Jan 7, 2015 in the journal Science Translational Medicine. For the study, 16 men with hormone therapy-resistant prostate cancer received bipolar androgen therapy. Of these patients, seven had their cancer go into remission. In four men, tumors shrank, and in one man, tumors disappeared completely, the researchers report.

Overall, "50 percent of patients had declines in their PSA prostate exact antigen and 50 percent had shrinkage of their cancer". PSA levels are a classic nod of prostate cancer activity, as dignified in a blood test. Senior swat architect Dr Samuel Denmeade is co-director of the prostate cancer program at Johns Hopkins University in Baltimore. He believes the fresh approach has benefits beyond its drift on cancer cells.

That's because restoring a man's testosterone levels also reduced the side property of hormone therapy, which include mood swings and not being able to have intercourse. "For the most part, men said they felt great. Most of the men felt take to they had more energy. Men on hormone remedying who couldn't have sex could have sex again, so they were very happy about that". And although testosterone levels alternated between towering and low, the men seemed to tolerate the treatment well.

Denmeade stressed that this treatment is not a cure, but a advance to make men feel better and extend the time standard hormonal therapy remains effective. "Maybe men will dwell longer, but we don't know that yet. According to Denmeade, men enrolled in the work didn't have any symptoms from their cancer, such as pain, and had been on standard hormonal analysis for an average of four years. They had also suffered a side effect of standard hormonal cure - impotence - for at least one year.

Bipolar androgen therapy is probably not for "men who have not yet had any care for prostate cancer". Moreover, the long-term effects or dangers of the therapy aren't yet known. Only longer, larger trials will facilitate uncover any risks associated with the treatment. And one mavin worries that alternating testosterone levels could actually shorten men's lives. "A cancer stall could escape and grow, as happened in breast cancer when this method was tried with estrogen, causing untimely death," said Dr Anthony D'Amico, chief of radiation oncology at Brigham and Women's Hospital in Boston helpful resources. D'Amico agreed with the observe authors that bipolar androgen remedy is not ready to be used in clinical practice and doctors should wait for the results of ongoing trials before present it to men.